Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Inclusion Criteria:

Patients: Who are 18 years of age and older Who have histologically
documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS
greater than 80%Life expectancy greater than 6 months Provide written consent pursuant to
regulatory requirements prior to initiation of study procedure

Exclusion Criteria:Exclusion Criteria: Patients: Any patient requiring continuous LHRH Any
patient who has had an orchiectomy Any patient with painful bone metastases Who have
received chemotherapy for prostate cancer Who have a abnormal serum creatine >2.5
Receiving any investigational drug within the last 28 days Severe uncontrolled infection,
diabetes, cardiac disease Patients with fragility fractures, hyperparathyroidism, Pagets
renal osteodystrophy will be excluded History of non compliance to medical regimens or
unwillingness to return for medical visits